Point72 Asset Management L.P. purchased a new stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 408,900 shares of the biopharmaceutical company’s stock, valued at approximately $4,723,000. Point72 Asset Management L.P. owned about 1.23% of Bellicum Pharmaceuticals as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Voya Investment Management LLC bought a new stake in shares of Bellicum Pharmaceuticals in the second quarter valued at approximately $132,000. Commonwealth Equity Services Inc bought a new stake in shares of Bellicum Pharmaceuticals in the third quarter valued at approximately $142,000. Nationwide Fund Advisors boosted its position in shares of Bellicum Pharmaceuticals by 30.4% in the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,620 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Bellicum Pharmaceuticals in the third quarter valued at approximately $189,000. Finally, ProShare Advisors LLC lifted its position in Bellicum Pharmaceuticals by 14.9% in the second quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 2,513 shares during the period. Institutional investors own 55.28% of the company’s stock.

In other news, CFO Alan A. Musso sold 6,206 shares of the firm’s stock in a transaction on Monday, November 27th. The stock was sold at an average price of $9.89, for a total value of $61,377.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alan A. Musso sold 17,117 shares of the firm’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $9.33, for a total value of $159,701.61. Following the completion of the sale, the chief financial officer now owns 31,585 shares of the company’s stock, valued at $294,688.05. The disclosure for this sale can be found here. Corporate insiders own 18.77% of the company’s stock.

Several brokerages recently commented on BLCM. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, September 18th. Jefferies Group reaffirmed a “buy” rating and issued a $16.00 target price on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Raymond James Financial reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Zacks Investment Research raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Bellicum Pharmaceuticals has an average rating of “Hold” and an average price target of $26.20.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) opened at $8.29 on Tuesday. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23. Bellicum Pharmaceuticals, Inc. has a 12 month low of $7.41 and a 12 month high of $15.57.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative return on equity of 77.16% and a negative net margin of 17,957.31%. The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.03 million. During the same period in the prior year, the company posted ($0.66) earnings per share. The business’s revenue for the quarter was up 18.2% compared to the same quarter last year. analysts predict that Bellicum Pharmaceuticals, Inc. will post -2.93 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Point72 Asset Management L.P. Takes $4.72 Million Position in Bellicum Pharmaceuticals, Inc. (BLCM)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/point72-asset-management-l-p-takes-4-72-million-position-in-bellicum-pharmaceuticals-inc-blcm/1772762.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.